Related Experiment Video
Updated: Dec 10, 2025

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Improving guideline-mandated care of patients with implantable cardiac defibrillators
Daniel Garner1, Matthew Blackburn2, David J Wright1
1Department of Cardiology, Liverpool Heart and Chest Hospital, Liverpool, UK.
Insights
Focused interventions improved timely deactivation of implantable cardiac defibrillators (ICDs). Enhanced patient understanding and communication led to more appropriate deactivation decisions at the end of life.
Area of Science:
- Cardiology
- Medical Device Technology
- Quality Improvement
Background:
- Implantable cardiac defibrillators (ICDs) reduce sudden cardiac death risk but lose value as disease progresses.
- Guidelines recommend reviewing ICD appropriateness and deactivation as patients near end of life.
- Patient understanding of health status and ICD role influences deactivation timing decisions.
Purpose of the Study:
- To improve appropriate deactivation of implantable cardiac defibrillators (ICDs).
- To enhance patient communication and documentation regarding ICD deactivation.
- To align ICD deactivation with patient-centered end-of-life care.
Main Methods:
- A quality improvement project was implemented in a tertiary cardiac center.
- Interventions included electronic records, clinical review for comorbid patients, and patient/carer education forums.
- Outcomes measured: number of deactivations, patient discussion/consent evidence, and deactivation timing.
Main Results:
- Timely ICD deactivations increased significantly post-intervention.
- Documented evidence of patient discussion and consent improved.
- The patient and carer educational forum was well-received.
Conclusions:
- Multidisciplinary interventions effectively increase appropriate ICD deactivation.
- Improved patient engagement and understanding facilitate informed deactivation decisions.
- Quality improvement initiatives can optimize end-of-life care for ICD recipients.
Background/Aims:
Implantable cardiac defibrillators reduce the risk of sudden cardiac death in selected patients. The value of an implantable cardiac defibrillator declines as the patient's disease progresses. Guidelines suggest that the appropriateness of maintaining implantable cardiac defibrillator therapy be regularly reviewed as part of monitoring of the patient's disease trajectory. It is recommended that implantable cardiac defibrillators are deactivated as patients approach the end of life. Patients with a better understanding of their current state of health and the role that the implantable cardiac defibrillator plays within it are more likely to make informed decisions about the timing of deactivation.
Methods:
A quality improvement project was undertaken on appropriate deactivation of implantable cardiac defibrillators within a large tertiary cardiac centre. This was driven by audit data showing inadequate patient communication and documentation around deactivation. Drivers for change included the introduction of electronic data records, clinical review of comorbid patients approaching elective battery change and an ongoing forum for patient and carer education. Measured outcomes included the number of deactivations performed, evidence of patient discussion and consent, and timing of deactivation of the implantable cardiac defibrillator.
Results:
There were increased numbers of timely device deactivations undertaken following the interventions with improved documented evidence of patient discussion and consent. The educational forum was received favourably.
Conclusions:
Focused multidisciplinary interventions can impact favourably on appropriate implantable cardiac defibrillator deactivation and improve patient engagement.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiopulmonary Resuscitation III: AED Use
Cardiac Catheterization IV: Nursing Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy

